Supernus flies high on FDA OK for Trokendi XR in epilepsy
This article was originally published in Scrip
Executive Summary
Investors rallied around shares of Supernus Pharmaceuticals in a big way on 19 August, with the company's stock soaring as high as 26.5% after the US FDA granted its approval for the Rockville, Maryland specialty pharma to market its once-daily extended release formulation of topiramate under the brand-name Trokendi XR as a treatment for patients with epilepsy.
You may also be interested in...
Torrent Loses US Infringement Battle Over Supernus’ Trokendi XR
While a US district court sided with Supernus over its patent infringement claims against Torrent, the court’s opinion was sealed due to confidential and proprietary information.
Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.